Trevi Therapeutics (TRVI) Current Assets (2018 - 2026)

Trevi Therapeutics has reported Current Assets for 9 years, with the latest figure at $176.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 66.75% year-over-year to $176.1 million; the trailing twelve-month figure through Mar 2026 stood at $176.1 million (up 66.75% YoY), and the FY2025 full-year result was $191.7 million, up 75.14% from the prior year.
• Current Assets for Q1 2026 stood at $176.1 million, down from $191.7 million in the prior quarter.
• The five-year high for Current Assets was $207.2 million in Q2 2025, with the low at $29.8 million in Q1 2022.
• Average Current Assets over 5 years is $115.2 million, with a median of $105.6 million recorded in 2025.
• Year-over-year, Current Assets soared 314.62% in 2022 and sank 32.78% in 2024.
• Tracing TRVI's Current Assets over 5 years: stood at $122.6 million in 2022, then declined by 28.6% to $87.5 million in 2023, then advanced by 24.99% to $109.4 million in 2024, then surged by 75.14% to $191.7 million in 2025, then fell by 8.11% to $176.1 million in 2026.
• The last three Current Assets figures came in at $176.1 million (Q1 2026), $191.7 million (Q4 2025), and $198.3 million (Q3 2025), per Business Quant data.

Peer Comparison